However, at present, no CHEK1 inhibitors have been approved in Phase 3 clinical trials, due in part to cumulative normal tissue toxicities, off-target effects of simultaneous CHEK2 inhibition, and inefficient drug delivery in cancer patients [46, 48]. The gene discussed is CHEK2; the disease is cancer.